Day 1, Sessions I & II

 

SESSION I: Introduction and Keynote Address by Phillip Gattone, CEO and President, Epilepsy Foundation.

  • Welcome and Overview
    Warren Lammert, Chairman, Epilepsy Foundation 
    Jacqueline French, MD, Professor of Neurology, New York University, Co-Director Epilepsy Research and Epilepsy Clinical Trials, NYU Comprehensive Epilepsy Center
    Starts at 0:12
     
  • Keynote: Annual State of the Drug Pipeline
    Jacqueline French, MD, Professor of Neurology, New York University
    Starts at 9:00
     
  • Keynote: Annual State of the Device Pipeline
    Robert Fisher, MD, PhD, Maslah Saul MD, Professor of Neurology, Director Stanford Comprehensive Epilepsy Program
    Starts at 25:35

SESSION II: What was better in 2013 than 2012 -- Progress in Epilepsy Therapy, moderated by Jacqueline French, MD, Professor of Neurology, New York University

The session includes the following presentations:

  • FDA and Epilepsy Trials: Past, Present and Future
    Russell Katz, MD, Consultant, Epilepsy Study Consortium
    Starts at 44:27
     
  • Why Industry Should Keep Investing in Epilepsy
    Christopher Gallen, MD, PhD, President and CEO, SK Biopharmaceuticals | SK Life Sciences
    Starts at 1:17:34
     
  • The NINDS ASP: Yesterday, Today and Tomorrow
    John Kehne, PhD, Program Director, National Institute of Health, National Institute of Neurological Disorders and Stroke 
    H. Steve White, PhD, Professor and Director, Anticonvulsant Drug Development Program, University of Utah
    Starts at 1:34:25
     
  • Epilepsy Therapies: Accomplishments and Challenges
    Roger J. Porter, MD, CSO, Epilepsy Foundation
    Starts at 2:06:10

>>Next Video: 
Day 1, Early-Stage Drug Pipeline: Proof of Principle through IND